CAMP earnings analysis
What we found in CAMP's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
CAMP4 reported $1.779 million of second-quarter revenue and diluted EPS of $(0.58), with revenue up 19% year over year but net loss reaching $33.530 million, including a $20.930 million non-cash derivative liability loss. The $46.9 million of August financing proceeds, combined with $86.4 million of cash at June 30, 2026, extends management's stated funding runway through the end of 2028, although additional capital will ultimately be required. The principal near-term catalyst is the planned CMP-002 Phase 1/2 trial launch in the fourth quarter of 2026, subject to regulatory and ethics approvals.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue increased year over year
- Second-quarter revenue was $1.779 million, up 19% year over year and higher than approximately $1.0 million in the prior quarter. The company remains pre-commercial and has not generated product revenue.
- Financing extends stated runway
- Cash and cash equivalents were $86.4 million at June 30, 2026. Including $46.9 million of net proceeds from the August 2026 private-placement second closing, management estimates funding through the end of 2028.
- CMP-002 trial launch remains targeted
- CAMP4 received regulatory clearance in Australia and Argentina to initiate the CMP-002 Phase 1/2 trial and expects to begin the trial in the fourth quarter of 2026.
- No control deficiencies reported
- Management stated that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026, with no material changes in internal control during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Large derivative-related loss
- Net loss was $33.530 million for the quarter, including a $20.930 million non-cash loss from the derivative liability. The large loss increases dependence on future financing despite the stated runway through 2028.
- Continued need for additional capital
- The filing states that cash and cash equivalents of $86.4 million plus $46.9 million of August 2026 financing proceeds may fund operations only through the end of 2028, and that additional capital will still be required to advance candidates through development and commercialization.
- Clinical and regulatory execution risk
- CMP-002 has not yet entered clinical trials; the company intends to start its Phase 1/2 trial in the fourth quarter of 2026. Regulatory authorities or ethics committees could require additional preclinical work or impose other requirements that delay the trial and increase costs.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.58
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management stated that $86.4 million of cash and cash equivalents as of June 30, 2026, together with $46.9 million of net proceeds received in August 2026, is expected to fund operating expenses and capital expenditures through the end of 2028. Management also expects to initiate the CMP-002 Phase 1/2 clinical trial in the fourth quarter of 2026.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- CAMP4 Therapeutics' Q1 2026 results show revenue growth to $1.294 million, surpassing the prior year by 51%. However, this was overshadowed by a significant net loss of $18.3 million, widening from $12.4 million a year…
- 10-K · March 5, 2026
- CAMP4 positions itself as a platform company building a proprietary RAP Platform to identify regRNAs and create ASO therapeutics (it says it has identified “tens of thousands of regRNA sequences” and can map multiple…
- 10-Q · August 14, 2025
- CAMP4 reported Q2 revenue of $1,497,000 (first revenue vs $0 in Q2 2024) and GAAP diluted EPS of $(0.62). Operating loss was $(13,028,000) (operating margin -870.3%) while cash and cash equivalents declined to…
- 10-K · March 27, 2025
- CAMP4 positions itself as a platform-driven RNA therapeutics company (RAP Platform) aiming to upregulate gene expression with ASO‑based "RNA Actuators," led by clinical‑stage CMP‑CPS‑001 for urea cycle disorders. The…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CAMP makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever